<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tuberous sclerosis complex: Clinical features</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tuberous sclerosis complex: Clinical features</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Tuberous sclerosis complex: Clinical features</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephanie Randle, MD, MS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Helen V Firth, DM, FRCP, FMedSci</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alberto S Pappo, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marc C Patterson, MD, FRACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Dashe, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 08, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Tuberous sclerosis complex (TSC) is an inherited neurocutaneous disorder that is characterized by pleomorphic features involving many organ systems, including multiple benign hamartomas of the brain, eyes, heart, lung, liver, kidney, and skin [<a href="#rid1">1-3</a>]. The expression of the disease varies substantially. The diagnosis of TSC can be made clinically or through genetic testing.</p><p>The clinical features of TSC will be reviewed here. Other aspects of TSC are discussed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/142618.html" rel="external">"Tuberous sclerosis complex: Genetics and pathogenesis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/143210.html" rel="external">"Tuberous sclerosis complex: Evaluation and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16902.html" rel="external">"Tuberous sclerosis complex: Management and prognosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1684.html" rel="external">"Renal manifestations of tuberous sclerosis complex"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4329.html" rel="external">"Tuberous sclerosis complex associated lymphangioleiomyomatosis in adults"</a>.)</p><p></p><p class="headingAnchor" id="H3097125473"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Most reports suggest the incidence of TSC is 1 in 6000 to 1 in 10,000 live births [<a href="#rid3">3-9</a>]. The incidence does not differ by sex or race/ethnicity [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H3700944295"><span class="h1">VARIABLE PHENOTYPE</span><span class="headingEndMark"> — </span>TSC is characterized by the development of a variety of benign tumors in multiple organs, including the brain, heart, skin, eyes, kidney, lung, and liver [<a href="#rid3">3,11</a>]. Nearly all patients with TSC have one or more of the skin lesions that are characteristic of the disorder. Many patients with TSC have epilepsy, and one-half or more have cognitive deficits and learning disabilities. However, there is a wide variety of phenotypes among and within families regarding the number and severity of TSC manifestations [<a href="#rid12">12,13</a>]. The classic Vogt diagnostic triad, consisting of seizures, intellectual disability, and facial angiofibromas [<a href="#rid14">14</a>], occurs in less than one-third of patients with TSC [<a href="#rid2">2</a>].</p><p>Possible manifestations of TSC reported in occasional patients include vascular anomalies, limb overgrowth (hemihypertrophy), and segmental lymphedema [<a href="#rid15">15-18</a>].</p><p>In addition, there is an increased risk of malignancy in TSC. (See  <a class="medical medical_review" href="/z/d/html/16902.html" rel="external">"Tuberous sclerosis complex: Management and prognosis", section on 'Risk of invasive malignancy'</a>.)</p><p class="headingAnchor" id="H3059341299"><span class="h1">PRESENTATION</span><span class="headingEndMark"> — </span>TSC is a progressive disorder, but the individual features have different natural histories. In addition, because the expression of TSC varies significantly among patients and within families, it is difficult to predict the extent to which a child with newly diagnosed disease will be affected.</p><p class="headingAnchor" id="H1822615860"><span class="h2">Infancy</span><span class="headingEndMark"> — </span>Common presentations of TSC in infancy include seizures, hypomelanotic macules, and detection of cardiac rhabdomyoma [<a href="#rid19">19-21</a>].</p><p>In a longitudinal study of 125 patients with TSC, the median age at presentation was seven months [<a href="#rid19">19</a>]. Seizures were the most common presentation of TSC in infancy or early childhood, accounting for 62 percent of cases. An abnormality on prenatal ultrasound, mainly cardiac rhabdomyoma, was the second most common presentation, accounting for 14 percent of cases. Presentation before the onset of seizures was not uncommon, occurring in 24 percent. Similarly, a retrospective review that included 101 infants with TSC diagnosed within the first week to 12 months of life found that most presented with new-onset seizures, infantile spasms, or hypomelanotic macules [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H842671358"><span class="h2">Childhood</span><span class="headingEndMark"> — </span>TSC often presents with seizures in childhood (see <a class="local">'Seizures and epilepsy'</a> below), and many of the dermatologic features of TSC become apparent during childhood, when hypomelanotic macules and forehead plaque are seen, or during adolescence, when angiofibromas of the face become visible. (See <a class="local">'Dermatologic manifestations'</a> below.)</p><p>Complications caused by the growth of subependymal giant cell astrocytomas (also known as subependymal giant cell tumors) are also most likely to occur during childhood, with these lesions stabilizing in the teens to twenties. (See <a class="local">'Brain lesions'</a> below.)</p><p>In a retrospective review, there were 74 children with TSC diagnosed from age 1 to 10 years, and most presented with new-onset seizures or a history of seizures [<a href="#rid20">20</a>]. In addition, a family history of TSC and dermatologic features were common presenting features. Among 16 patients diagnosed from ages 11 to 20 years, the most common presenting features were new-onset seizures and angiofibromas.</p><p class="headingAnchor" id="H3393143077"><span class="h2">Adulthood</span><span class="headingEndMark"> — </span>Features of TSC that are likely to first present in adulthood as significant problems include renal angiomyolipoma, periungual fibroma, and lymphangioleiomyomatosis. (See <a class="local">'Dermatologic manifestations'</a> below and <a class="local">'Renal manifestations'</a> below and <a class="local">'Pulmonary manifestations'</a> below.)</p><p>The diagnosis of TSC is sometimes made in adults after the diagnosis is made in an affected child, particularly if the parent is mosaic for a TSC complex subunit 1 (<em>TSC1</em>)<em>/</em>TSC complex subunit 2 (<em>TSC2</em>) pathogenic variant and is mildly affected. In a retrospective review that included 23 patients diagnosed with TSC as adults, most presented because of a new diagnosis in a family member or a known family history of TSC [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/z/d/html/143210.html" rel="external">"Tuberous sclerosis complex: Evaluation and diagnosis", section on 'Parental evaluation'</a>.)</p><p class="headingAnchor" id="H17"><span class="h1">BRAIN LESIONS</span></p><p class="headingAnchor" id="H1119695796"><span class="h2">Glioneuronal hamartomas and subependymal nodules</span><span class="headingEndMark"> — </span>Both cortical glioneuronal hamartomas and subependymal nodules (SENs) are regarded as hamartomas (a benign mass of disorganized tissue native to a particular anatomic location).</p><p class="bulletIndent1"><span class="glyph">●</span>Cortical glioneuronal hamartomas  (<a class="graphic graphic_diagnosticimage graphicRef71505" href="/z/d/graphic/71505.html" rel="external">image 1</a>) are composed histologically of enlarged atypical and disorganized neuronal and glial elements with astrocytosis. In keeping with their hamartomatous nature, "glioneuronal hamartoma" is preferred in place of the outdated term "tuber" when describing a finding in patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>SENs are also composed of atypical enlarged glial and neuronal cells. These nodules  (<a class="graphic graphic_diagnosticimage graphicRef52792" href="/z/d/graphic/52792.html" rel="external">image 2</a>) are indistinguishable histologically from subependymal giant cell astrocytomas (SEGAs), also known as subependymal giant cell tumors (SGCTs)  (<a class="graphic graphic_diagnosticimage graphicRef64578" href="/z/d/graphic/64578.html" rel="external">image 3</a>), except for their small size. (See <a class="local">'Subependymal giant cell astrocytomas'</a> below.)</p><p></p><p>Cortical glioneuronal hamartomas and SENs are present on brain magnetic resonance imaging (MRI) in approximately 90 percent of children with TSC [<a href="#rid19">19,22,23</a>]. The detection rate of these lesions is moderately lower on computed tomography (CT). Cortical glioneuronal hamartomas may be calcified on CT scan in approximately one-half of patients, and SENs are usually calcified on CT except in the early years of life [<a href="#rid22">22,24,25</a>]. To minimize radiation exposure, the use of CT monitoring for children with TSC should be limited. (See  <a class="medical medical_review" href="/z/d/html/6214.html" rel="external">"Ischemic stroke in children: Clinical presentation, evaluation, and diagnosis", section on 'CT safety considerations'</a>.)</p><p>The extent of cerebral dysfunction (ie, seizure status and cognitive function) in TSC is only loosely related to the burden of glioneuronal hamartomas as demonstrated on cranial imaging. In a meta-analysis of five studies, the number of MRI-detected glioneuronal hamartomas in patients with TSC and severe cerebral dysfunction (ie, poor seizure control and/or moderate to severe intellectual disability) was six times more likely to be above the median compared with mildly affected patients [<a href="#rid26">26</a>]. Because glioneuronal hamartomas form during embryogenesis, disruption of normal cortical development and function occurs early in gestation. In a later study of 61 patients with TSC, the proportion of brain volume occupied by glioneuronal hamartomas was inversely related both to age at seizure onset and to cognitive function [<a href="#rid27">27</a>]. However, the relationship was not invariant, as some patients with a large glioneuronal hamartoma volume had normal intelligence. Cortical glioneuronal hamartomas with central low signal on fluid-attenuated inversion recovery (FLAIR) MRI may predict a higher risk of epilepsy in TSC [<a href="#rid28">28</a>]. (See <a class="local">'Seizures and epilepsy'</a> below.)</p><p class="headingAnchor" id="H1119695784"><span class="h2">Subependymal giant cell astrocytomas</span><span class="headingEndMark"> — </span>The characteristic brain tumor in TSC is the SEGA  (<a class="graphic graphic_diagnosticimage graphicRef64578" href="/z/d/graphic/64578.html" rel="external">image 3</a> and <a class="graphic graphic_picture graphicRef91047" href="/z/d/graphic/91047.html" rel="external">picture 1</a>), which is a benign, slow-growing tumor that usually arises in the periventricular area [<a href="#rid29">29-32</a>]. SEGAs are thought to arise from the growth of SENs. Although most often called "subependymal giant cell astrocytomas," they are of mixed glioneuronal lineage; thus "subependymal giant cell tumors" is a more accurate description.</p><p>The prevalence of SEGAs in TSC ranges from 5 to 20 percent in different studies [<a href="#rid5">5</a>]. As noted, the distinction between SENs and SEGAs may be largely semantic.</p><p>Evidence from radiologic studies supports the hypothesis that SEGAs can arise from the growth of preexisting SENs, the latter occurring in 88 to 95 percent of children with TSC [<a href="#rid33">33-35</a>]. However, the apparent absence of SENs on neuroimaging does not eliminate the risk of developing a SEGA. It is not clear why some SENs grow (and therefore are termed SEGAs) while others do not. Neoplastic transformation of SENs/SEGAs is rare.</p><p>Symptomatic SEGAs occur in 6 to 9 percent of individuals with TSC [<a href="#rid29">29,36,37</a>]. The tumors usually become symptomatic between the ages of 10 and 30, although they can occur as early as 1.5 years [<a href="#rid31">31,38</a>]. Affected children typically present subacutely with signs and symptoms of obstructive hydrocephalus, such as headaches and vomiting, or with focal neurologic deficits, including vision loss [<a href="#rid29">29-31,36,39</a>]. In addition, children may present with nonspecific symptoms such as fatigue, depression, decreased appetite, and increased seizure frequency [<a href="#rid29">29</a>].</p><p>Diagnostic features associated with increased morbidity are likely to have the most clinical utility for decision-making regarding subependymal lesions (whether SENs or SEGAs); these include [<a href="#rid29">29</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>New symptoms or papilledema</p><p class="bulletIndent1"><span class="glyph">●</span>Hydrocephalus</p><p class="bulletIndent1"><span class="glyph">●</span>Growth of the lesion on serial imaging</p><p></p><p>In most cases, the presence of these criteria should define the lesion as a SEGA rather than a SEN, independent of tumor size, location, signal characteristics, or contrast enhancement [<a href="#rid29">29</a>]. Radiologic evidence of hydrocephalus may not be prominent on neuroimaging studies in patients with TSC even when increased intracranial pressure due to SEGA is present; in such cases new symptoms or papilledema may be present, perhaps due to altered periventricular compliance [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H1119695768"><span class="h2">White matter lesions</span><span class="headingEndMark"> — </span>White matter lesions are common in patients with TSC [<a href="#rid40">40</a>]. These include nodules, cysts, and areas of gliosis and hypomyelination. Linear white matter lesions may be visualized by MRI in approximately 15 percent of children with TSC [<a href="#rid40">40</a>]. These linear lesions are hyperintense on T2-weighted MRI and are either isointense or hypointense on T1 images. They typically extend from the ventricle to the cortex, with a SEN or subcortical lesion on each end; they are thought to represent demyelination, dysmyelination, or hypomyelination from a migration disorder [<a href="#rid41">41</a>].</p><p>Microscopic white matter lesions are characteristically present in patients with TSC [<a href="#rid42">42</a>]. Even normal-appearing white matter may show pathologically increased water diffusivity (ie, an increased apparent diffusion coefficient) by diffusion-weighted MRI [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H649028360"><span class="h2">Arachnoid cysts</span><span class="headingEndMark"> — </span>In a retrospective review of brain MRIs from 220 patients with TSC, asymptomatic arachnoid cysts were noted in approximately 5 percent; this compares with an estimated prevalence in the general population of 0.5 to 1 percent [<a href="#rid44">44</a>]. Thus, arachnoid cysts may be part of the clinical spectrum of TSC.</p><p class="headingAnchor" id="H25"><span class="h1">SEIZURES AND EPILEPSY</span><span class="headingEndMark"> — </span>Seizures are the most frequent presenting feature of TSC, and epilepsy is one of the most frequent and significant causes of morbidity in TSC, affecting 79 to 90 percent of patients in population-based studies [<a href="#rid19">19,45</a>]. Seizures begin in the first year of life in just over 60 percent of cases; however, patients with TS remain at risk for new-onset seizures into adult life [<a href="#rid19">19,46,47</a>]. In a natural history study that included 248 patients with TSC who had a single seizure, epilepsy subsequently developed in 246 (99 percent) [<a href="#rid47">47</a>].</p><p>Despite the frequency of seizures in TSC, epilepsy is not one of the diagnostic criteria because of the large number of disorders that are associated with seizures, including infantile spasms. (See  <a class="medical medical_review" href="/z/d/html/143210.html" rel="external">"Tuberous sclerosis complex: Evaluation and diagnosis", section on 'Diagnosis'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Seizure types</strong> – Infantile spasms are the most common type in infancy at initial diagnosis, occurring in 36 to 69 percent of patients [<a href="#rid48">48</a>]. Conversely, up to 25 percent of children with infantile spasms may have TSC [<a href="#rid49">49</a>]. (See  <a class="medical medical_review" href="/z/d/html/6145.html" rel="external">"Infantile epileptic spasms syndrome: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1">Other seizure types that occur in TSC include focal-onset seizures with and without impaired awareness, focal-onset to bilateral tonic-clonic seizures (previously termed secondarily generalized), subclinical seizures, and, less commonly, generalized onset seizures [<a href="#rid47">47,50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>EEG findings</strong> – Approximately 75 percent of patients with TSC have epileptiform abnormalities on routine electroencephalography (EEG). These include focal or multifocal discharges, hypsarhythmia, and generalized spike-wave abnormalities in 48, 19, and 8 percent, respectively [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Risk factors for the development of epilepsy include the presence of cortical glioneuronal hamartomas (tubers) and pathogenic <em>TSC2</em> variants [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent1">Cortical glioneuronal hamartomas with central low signal on fluid-attenuated inversion recovery (FLAIR) MRI may predict a higher risk of epilepsy in TSC [<a href="#rid28">28</a>]. The majority of cortical glioneuronal hamartomas show homogeneous high signal on FLAIR MRI. However, some cortical glioneuronal hamartomas, sometimes called "cyst-like" though they are not true cysts, show central low signal intensity on FLAIR and T1-weighted sequences and increased signal on T2-weighted sequences. In a retrospective study of 173 patients with TSC, epilepsy was significantly more frequent in patients with at least one cortical glioneuronal hamartoma of low FLAIR and T1 signal intensity compared with those without (92 versus 76 percent, relative risk [RR] 1.22, 95% CI 1.07-1.40) [<a href="#rid28">28</a>]. Similarly, refractory epilepsy was significantly more common in patients with at least one cortical glioneuronal hamartoma of low FLAIR and T1 signal intensity (80 versus 54 percent, RR 1.47, 95% CI 1.18-1.83).</p><p></p><p class="bulletIndent1">Not all cortical glioneuronal hamartomas are epileptogenic, and patients with TSC and epilepsy may have normal brain MRI studies, raising significant questions about the role of glioneuronal hamartomas in producing seizures [<a href="#rid52">52</a>]. Furthermore, epileptic foci can shift over time.</p><p></p><p class="headingAnchor" id="H428016551"><span class="h1">TSC-ASSOCIATED NEUROPSYCHIATRIC DISORDERS (TAND)</span><span class="headingEndMark"> — </span>Most patients with TSC have one or more of the disorders that comprise TAND. These include intellectual disability, autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD), behavioral problems, psychiatric disorders, neuropsychologic deficits, school problems, and occupational difficulties [<a href="#rid53">53,54</a>]. These problems are often associated with brain lesions including glioneuronal hamartomas (also called tubers), periventricular giant cell astrocytomas, and abnormalities of cerebral white matter detected on neuroimaging studies [<a href="#rid1">1,55</a>]. (See <a class="local">'Brain lesions'</a> above.)</p><p class="headingAnchor" id="H27"><span class="h2">Intellectual disability</span><span class="headingEndMark"> — </span>Intellectual disability is a primary feature of TSC, affecting 44 to 65 percent of patients in population-based reports [<a href="#rid19">19,45</a>]. It is associated with a history of infantile spasms [<a href="#rid45">45,47,56,57</a>], refractory seizures [<a href="#rid47">47,58,59</a>], and, to a lesser extent, number of glioneuronal hamartomas [<a href="#rid60">60,61</a>]. In a cohort of over 1600 patients from a TSC database, epilepsy onset before the age of two years was associated with a higher frequency and severity of intellectual disability [<a href="#rid62">62</a>]. Epilepsy was also associated with autism and attention deficit hyperactivity disorder. (See  <a class="medical medical_review" href="/z/d/html/610.html" rel="external">"Specific learning disorders in children: Clinical features", section on 'Risk factors'</a>.)</p><p>There are conflicting data as to whether intellectual disability is less frequent with pathogenic variants involving <em>TSC1</em> compared with those involving <em>TSC2</em>, a question that is further complicated by a potential association between <em>TSC2</em> and an increased risk for epilepsy, including infantile spasms [<a href="#rid47">47,59</a>]. (See  <a class="medical medical_review" href="/z/d/html/142618.html" rel="external">"Tuberous sclerosis complex: Genetics and pathogenesis", section on 'Genotype-phenotype correlations'</a>.)</p><p>Like other features of TSC, the range of intelligence in affected patients is highly variable. In one study of standardized testing in 108 patients with TSC, intelligence quotient (IQ) scores had a bimodal distribution [<a href="#rid45">45</a>]. In 55 percent of patients, IQ was in the normal range, while 14 percent had mild to severe impairment, and 30 percent had profound disability (IQ &lt;21). Even among the children with a normal range IQ, scores were 10 points lower on average than their unaffected siblings. All the children with learning disabilities had a history of seizures, usually infantile spasms, which began before one year of age.</p><p>A history of immunization for diphtheria, tetanus, and pertussis was <strong>not</strong> a risk factor for poor cognitive development in a review of 106 patients with TSC [<a href="#rid56">56</a>].</p><p class="headingAnchor" id="H1266266509"><span class="h2">Autism spectrum disorder</span><span class="headingEndMark"> — </span>ASD and autistic behaviors, including hyperactivity, inattention, and self-injurious behavior, are common in children with TSC and can be a significant source of stress for parents and caregivers [<a href="#rid63">63-68</a>]. In different case series, the prevalence of significant behavioral problems among children with TSC ranges from 40 to 90 percent. While behavioral problems can occur in the setting of either normal intelligence or cognitive dysfunction, at least one case series found that low intellectual functioning and higher seizure frequency were risk factors for behavioral disorders [<a href="#rid66">66</a>].</p><p>Whether ASD is associated with a specific location of glioneuronal hamartomas is uncertain. In one study, development of ASD was associated with the presence of temporal lobe glioneuronal hamartomas, temporal lobe epileptiform discharges, and early onset of persistent infantile spasms [<a href="#rid69">69</a>]. Another study evaluated 115 patients with TSC, including 31 with ASD, and found that glioneuronal hamartoma (tuber) in the right fusiform face area of the inferior temporal lobe was associated with an increased risk of ASD (odds ratio 3.69, 95% CI 1.53-8.93) [<a href="#rid70">70</a>]. However, others have shown that the frequency of glioneuronal hamartomas in the subcortical or cortical regions was similar in TSC patients with and without ASD [<a href="#rid53">53,71</a>].</p><p>The clinical features and diagnosis of ASD are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/627.html" rel="external">"Autism spectrum disorder in children and adolescents: Clinical features"</a> and  <a class="medical medical_review" href="/z/d/html/628.html" rel="external">"Autism spectrum disorder in children and adolescents: Evaluation and diagnosis", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H1136060699"><span class="h2">Attention deficit hyperactivity disorder</span><span class="headingEndMark"> — </span>The estimated prevalence of ADHD in individuals with TSC ranges from 30 to 50 percent [<a href="#rid72">72-74</a>]. This prevalence is much higher than the prevalence of ADHD in the general population. The risk of ADHD in TSC has been associated with frontal lobe seizures or EEG abnormalities and pathogenic variants in <em>TSC2</em>, but causation has not been established [<a href="#rid72">72,73,75</a>]. (See  <a class="medical medical_review" href="/z/d/html/624.html" rel="external">"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/1232.html" rel="external">"Attention deficit hyperactivity disorder in adults: Epidemiology, clinical features, assessment, and diagnosis"</a>.)</p><p class="headingAnchor" id="H614337110"><span class="h2">Behavioral problems</span><span class="headingEndMark"> — </span>One-third or more of individuals with TSC exhibit at least one behavioral problem, which includes behaviors that are not psychiatric disorders but can cause difficulties for patients and families [<a href="#rid72">72,76</a>]. The types of problems include the following [<a href="#rid72">72</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Overactivity</p><p class="bulletIndent1"><span class="glyph">●</span>Impulsivity</p><p class="bulletIndent1"><span class="glyph">●</span>Sleep difficulties</p><p class="bulletIndent1"><span class="glyph">●</span>Anxiety</p><p class="bulletIndent1"><span class="glyph">●</span>Mood swings</p><p class="bulletIndent1"><span class="glyph">●</span>Aggressive behaviors</p><p class="bulletIndent1"><span class="glyph">●</span>Temper tantrums</p><p class="bulletIndent1"><span class="glyph">●</span>Poor eye contact</p><p class="bulletIndent1"><span class="glyph">●</span>Repetitive and ritualistic behaviors</p><p class="bulletIndent1"><span class="glyph">●</span>Speech and language delay</p><p></p><p class="headingAnchor" id="H2355373467"><span class="h1">SYSTEMIC INVOLVEMENT</span></p><p class="headingAnchor" id="H698291355"><span class="h2">Dermatologic manifestations</span><span class="headingEndMark"> — </span>In population-based studies, 81 to 95 percent of patients with TSC have one of the characteristic skin lesions [<a href="#rid19">19,77</a>]. The most common lesions are:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypomelanotic macules</strong> – Also known as hypopigmented macules or ash-leaf spots, hypomelanotic macules are usually elliptic in shape and may require evaluation with a Wood's lamp (ultraviolet) to visualize  (<a class="graphic graphic_picture graphicRef61601" href="/z/d/graphic/61601.html" rel="external">picture 2</a> and <a class="graphic graphic_picture graphicRef91042" href="/z/d/graphic/91042.html" rel="external">picture 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fibrous cephalic plaques</strong> – These are distinctive brown fibrous plaques on the forehead, which may be the first and most readily recognized feature of TSC to be appreciated on physical examination of affected neonates and infants  (<a class="graphic graphic_picture graphicRef78688" href="/z/d/graphic/78688.html" rel="external">picture 4</a>) [<a href="#rid77">77</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Angiofibromas</strong> – Also known as fibroadenomas, angiofibromas are benign tumors that typically involve the malar regions of the face  (<a class="graphic graphic_picture graphicRef54868" href="/z/d/graphic/54868.html" rel="external">picture 5</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ungual fibromas</strong> – Also known as periungual or subungual fibromas (Koenen tumors), ungual fibromas are erythematous, polypoid, digitated growths. They may produce a longitudinal groove in the nail plate due to matrix compression  (<a class="graphic graphic_picture graphicRef85599" href="/z/d/graphic/85599.html" rel="external">picture 6</a> and <a class="graphic graphic_picture graphicRef91046" href="/z/d/graphic/91046.html" rel="external">picture 7</a>).</p><p></p><p class="bulletIndent1">Ungual fibromas may develop during adolescence or adulthood  (<a class="graphic graphic_picture graphicRef91046" href="/z/d/graphic/91046.html" rel="external">picture 7</a>), and they occur more commonly on the toenails than on the fingernails [<a href="#rid77">77-79</a>]. Given the variable age of onset, it is important for the clinician to inspect the nails of both the patient and the parents when first doing an evaluation for TSC. Longitudinal nail grooves without visible fibromas are also commonly seen [<a href="#rid78">78</a>]. Less frequent acral lesions include subungual red comets (red longitudinal streaks with a larger distal head and a narrowing proximal tail), splinter hemorrhages, and longitudinal leukonychia (white streaks extending from the nail matrix to the end of the nail).</p><p></p><p class="bulletIndent1">A solitary ungual fibroma as a result of trauma is not a diagnostic feature of TSC [<a href="#rid7">7,80</a>]. On the other hand, a history of trauma in a patient presenting with an ungual fibroma should not be used to discount the possibility of TSC [<a href="#rid78">78</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Shagreen patches</strong> – These are connective tissue nevi, seen most commonly over the lower back  (<a class="graphic graphic_picture graphicRef91045" href="/z/d/graphic/91045.html" rel="external">picture 8</a>) [<a href="#rid81">81</a>]. </p><p></p><p>Hypomelanotic macules and fibrous cephalic plaques typically appear earlier than facial angiofibromas or ungual fibromas [<a href="#rid77">77</a>].</p><p>There is no significant risk of malignant transformation of skin lesions, which tend to increase in size and number through puberty and then tend to be stable over time.</p><p class="headingAnchor" id="H389235998"><span class="h2">Ophthalmic manifestations</span><span class="headingEndMark"> — </span>Ophthalmic findings in TSC include both retinal and nonretinal abnormalities and are useful in making the diagnosis. These lesions rarely affect vision and do not require specific treatment [<a href="#rid82">82</a>].</p><p>The prevalence of ophthalmic features was described in a report of 100 TSC patients (median age 27, range 2 to 76 years) [<a href="#rid83">83</a>]. The following findings were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>Retinal hamartomas were seen in 44 patients. These included a flat, translucent lesion, the most common type, in 31 (70 percent), a multilobular mulberry lesion  (<a class="graphic graphic_picture graphicRef78314" href="/z/d/graphic/78314.html" rel="external">picture 9</a>) in 24 (55 percent), and a transitional lesion with features of the two other types in four (9 percent). Calcification of the multilobular lesions results in the classic mulberry appearance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Punched-out areas of chorioretinal depigmentation (ie, retinal achromic patches) in the midperiphery of the retina were seen in 39 patients compared with only 6 of 100 controls.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nonretinal lesions included angiofibromas of the eyelids (in 39 of 100 patients), nonparalytic strabismus (in five), colobomas (in three), and sector iris depigmentation (in two).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among the refractive errors noted were myopia, hyperopia, and astigmatism &gt;0.75 D in 27, 22, and 27 percent of eyes, respectively; these values are similar to those expected for the general population.</p><p></p><p class="headingAnchor" id="H3662026072"><span class="h2">Oral and dental manifestations</span><span class="headingEndMark"> — </span>TSC is associated with the development of intraoral fibromas, gingival hyperplasia, dental enamel pits, and deforming jaw bone cysts [<a href="#rid84">84-87</a>].</p><p class="headingAnchor" id="H230292317"><span class="h2">Cardiovascular manifestations</span><span class="headingEndMark"> — </span>The characteristic cardiac feature of TSC is a rhabdomyoma, a benign tumor that often presents as multiple lesions. Cardiac rhabdomyomas are one of the most common pediatric cardiac tumors. (See  <a class="medical medical_review" href="/z/d/html/4881.html" rel="external">"Cardiac tumors", section on 'Rhabdomyomas'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rhabdomyomas</strong> – Most infants and children who have cardiac rhabdomyomas have TSC [<a href="#rid88">88</a>]. However, rhabdomyomas are not a universal finding in children with TSC. In one longitudinal series of 125 patients with TSC, rhabdomyomas were found overall in 58 percent, including 61 percent of children ages 0 to 4, and 36 percent of children ages 5 to 18 [<a href="#rid19">19</a>]. Rhabdomyomas associated with TSC are typically multifocal. Occasionally, cardiac rhabdomyomas appear as an isolated finding in TSC [<a href="#rid89">89</a>].</p><p></p><p class="bulletIndent1">Cardiac rhabdomyomas characteristically develop in utero and are often detected on prenatal ultrasound. In the longitudinal series of 125 patients with TSC, the finding of one or more rhabdomyomas before or soon after birth was the initial sign of TSC in 18 percent [<a href="#rid19">19</a>]. Although many rhabdomyomas are asymptomatic, patients with TSC and cardiac rhabdomyomas are most likely to be symptomatic in the newborn and early infancy period [<a href="#rid82">82,90</a>]. Thereafter, cardiac rhabdomyomas usually undergo spontaneous regression. The morbidity and mortality associated with these tumors reflect the potential for flow abnormalities if they grow to sufficient size to restrict blood flow. In one report that included 15 children with symptomatic cardiac rhabdomyoma (12 with TSC), the clinical presentation was heart failure or a cardiac murmur in six patients each and arrhythmia in three patients [<a href="#rid90">90</a>].</p><p></p><p class="bulletIndent1">There is no evidence that cardiac rhabdomyomas undergo malignant transformation, and no treatment is necessary for asymptomatic tumors, particularly when first noted in an older child or adult with TSC. (See  <a class="medical medical_review" href="/z/d/html/16902.html" rel="external">"Tuberous sclerosis complex: Management and prognosis", section on 'Cardiac involvement'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vascular pathologies</strong> – Coarctation of the aorta and constriction of major arteries (such as renal artery stenosis) are sometimes associated with TSC [<a href="#rid82">82</a>]. Aortic aneurysm may also occur [<a href="#rid15">15</a>].</p><p></p><p class="headingAnchor" id="H140867425"><span class="h2">Renal manifestations</span><span class="headingEndMark"> — </span>Renal lesions are common among patients with TSC, and their prevalence increases with age. Angiomyolipomas are the most frequent renal manifestation of TSC. Less often, benign cysts, lymphangiomas, and renal cell carcinoma occur. Progressive enlargement of angiomyolipomas and hemorrhage into the lesion can result in pain and interfere with renal function. The risk of hemorrhage increases with size. Patients with tuberous sclerosis and renal lesions may have renin-dependent hypertension and are at risk of developing chronic kidney disease due to replacement and compression of the renal parenchyma. These issues are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1684.html" rel="external">"Renal manifestations of tuberous sclerosis complex"</a>.)</p><p class="headingAnchor" id="H140867478"><span class="h2">Pulmonary manifestations</span><span class="headingEndMark"> — </span>Some adults with TSC develop pulmonary disease that is indistinguishable from the diffuse interstitial fibrosis known as lymphangioleiomyomatosis (LAM). This condition represents a cystic lung disease that can result in significant limitation in pulmonary function. The most common presenting features of LAM are dyspnea and pneumothorax. Among adults with TSC, the prevalence of LAM is higher for women than for men. The condition may worsen during pregnancy and can be a life-limiting complication of TSC.</p><p>LAM can occur as an isolated finding or can be associated with renal angiomyolipomas. As mentioned above, some women appear to have this combination as an isolated finding with no other features of TSC and no identifiable germline pathogenic variant in the <em>TSC1</em> or <em>TSC2</em> genes except in the LAM cells or angiomyolipoma.</p><p>The pulmonary manifestations of TSC and LAM are discussed in greater detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4329.html" rel="external">"Tuberous sclerosis complex associated lymphangioleiomyomatosis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/4335.html" rel="external">"Sporadic lymphangioleiomyomatosis: Epidemiology and pathogenesis"</a>.)</p><p class="headingAnchor" id="H3565749634"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/120578.html" rel="external">"Society guideline links: Tuberous sclerosis"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/118842.html" rel="external">"Society guideline links: Lymphangioleiomyomatosis"</a>.)</p><p class="headingAnchor" id="H140866924"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics</strong> – The genetics and pathogenesis of TSC are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/142618.html" rel="external">"Tuberous sclerosis complex: Genetics and pathogenesis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – TSC is characterized by a variety of benign tumors in multiple organs, including the brain, heart, skin, eyes, kidney, lung, and liver. There is also an increased risk of malignancy in TSC. (See <a class="local">'Variable phenotype'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Brain lesions</strong> – Brain lesions characteristic of TSC include glioneuronal hamartomas, also called cortical tubers  (<a class="graphic graphic_diagnosticimage graphicRef71505" href="/z/d/graphic/71505.html" rel="external">image 1</a>); white matter heterotopia; subependymal nodules (SENs)  (<a class="graphic graphic_diagnosticimage graphicRef52792" href="/z/d/graphic/52792.html" rel="external">image 2</a>); and subependymal giant cell astrocytomas (SEGAs), which are also known as subependymal giant cell tumors (SGCTs)  (<a class="graphic graphic_diagnosticimage graphicRef64578" href="/z/d/graphic/64578.html" rel="external">image 3</a>). (See <a class="local">'Brain lesions'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Epilepsy</strong> – Most patients with TSC have epilepsy, and one-half or more have cognitive deficits and learning disabilities. Autism and autistic behaviors are common in children with TSC. (See <a class="local">'Seizures and epilepsy'</a> above and <a class="local">'Intellectual disability'</a> above and <a class="local">'TSC-associated neuropsychiatric disorders (TAND)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>TSC-associated neuropsychiatric disorders (TAND)</strong> – Most patients with TSC have one or more of the disorders that make up TAND, which include intellectual disability, autism spectrum disorder, attention deficit hyperactivity disorder, behavioral problems, psychiatric disorders, neuropsychologic deficits, school problems, and occupational difficulties. (See <a class="local">'TSC-associated neuropsychiatric disorders (TAND)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Skin lesions</strong> – Nearly all patients with TSC have one or more of the skin lesions that are characteristic of the disorder. The most common skin lesions in TSC are hypomelanotic macules  (<a class="graphic graphic_picture graphicRef61601" href="/z/d/graphic/61601.html" rel="external">picture 2</a>), angiofibromas  (<a class="graphic graphic_picture graphicRef54868" href="/z/d/graphic/54868.html" rel="external">picture 5</a>), shagreen patches  (<a class="graphic graphic_picture graphicRef91045" href="/z/d/graphic/91045.html" rel="external">picture 8</a>), and fibrous plaques  (<a class="graphic graphic_picture graphicRef78688" href="/z/d/graphic/78688.html" rel="external">picture 4</a>). (See <a class="local">'Dermatologic manifestations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ophthalmic, cardiac, pulmonary, and renal manifestations</strong> – The characteristic cardiac feature of TSC is a rhabdomyoma. Angiomyolipomas are the most common renal manifestation of TSC. Benign cysts and lymphangiomas also can occur. Some adults with TSC develop pulmonary disease that is indistinguishable from the diffuse interstitial fibrosis known as lymphangioleiomyomatosis (LAM). Ophthalmic findings in TSC include both retinal and nonretinal abnormalities, although they rarely affect vision. (See <a class="local">'Cardiovascular manifestations'</a> above and <a class="local">'Renal manifestations'</a> above and <a class="local">'Pulmonary manifestations'</a> above and <a class="local">'Ophthalmic manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation, diagnosis, and</strong> <strong>management</strong> – These aspects of TSC are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/143210.html" rel="external">"Tuberous sclerosis complex: Evaluation and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/16902.html" rel="external">"Tuberous sclerosis complex: Management and prognosis"</a>.)</p><p></p><p class="headingAnchor" id="H753461254"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Sharon Plon, MD, PhD, James Owens, MD, PhD, and John B Bodensteiner, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med 2006; 355:1345.</a></li><li><a class="nounderline abstract_t">Schwartz RA, Fernández G, Kotulska K, Jóźwiak S. Tuberous sclerosis complex: advances in diagnosis, genetics, and management. J Am Acad Dermatol 2007; 57:189.</a></li><li><a class="nounderline abstract_t">Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet 2008; 372:657.</a></li><li><a class="nounderline abstract_t">Osborne JP, Fryer A, Webb D. Epidemiology of tuberous sclerosis. Ann N Y Acad Sci 1991; 615:125.</a></li><li><a class="nounderline abstract_t">Hallett L, Foster T, Liu Z, et al. Burden of disease and unmet needs in tuberous sclerosis complex with neurological manifestations: systematic review. Curr Med Res Opin 2011; 27:1571.</a></li><li><a class="nounderline abstract_t">Hong CH, Tu HP, Lin JR, Lee CH. An estimation of the incidence of tuberous sclerosis complex in a nationwide retrospective cohort study (1997-2010). Br J Dermatol 2016; 174:1282.</a></li><li><a class="nounderline abstract_t">Northrup H, Aronow ME, Bebin EM, et al. Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatr Neurol 2021; 123:50.</a></li><li><a class="nounderline abstract_t">Ebrahimi-Fakhari D, Mann LL, Poryo M, et al. Correction to: Incidence of tuberous sclerosis and age at first diagnosis: new data and emerging trends from a national, prospective surveillance study. Orphanet J Rare Dis 2019; 14:106.</a></li><li><a class="nounderline abstract_t">Ebrahimi-Fakhari D, Mann LL, Poryo M, et al. Incidence of tuberous sclerosis and age at first diagnosis: new data and emerging trends from a national, prospective surveillance study. Orphanet J Rare Dis 2018; 13:117.</a></li><li><a class="nounderline abstract_t">Peron A, Au KS, Northrup H. Genetics, genomics, and genotype-phenotype correlations of TSC: Insights for clinical practice. Am J Med Genet C Semin Med Genet 2018; 178:281.</a></li><li><a class="nounderline abstract_t">DiMario FJ Jr, Sahin M, Ebrahimi-Fakhari D. Tuberous sclerosis complex. Pediatr Clin North Am 2015; 62:633.</a></li><li><a class="nounderline abstract_t">Northrup H, Wheless JW, Bertin TK, Lewis RA. Variability of expression in tuberous sclerosis. J Med Genet 1993; 30:41.</a></li><li><a class="nounderline abstract_t">Lyczkowski DA, Conant KD, Pulsifer MB, et al. Intrafamilial phenotypic variability in tuberous sclerosis complex. J Child Neurol 2007; 22:1348.</a></li><li><a class="nounderline abstract_t">Goodrick S. The road to Vogt's triad. Lancet Neurol 2015; 14:690.</a></li><li><a class="nounderline abstract_t">Jost CJ, Gloviczki P, Edwards WD, et al. Aortic aneurysms in children and young adults with tuberous sclerosis: report of two cases and review of the literature. J Vasc Surg 2001; 33:639.</a></li><li><a class="nounderline abstract_t">Jenkins D, McCuaig C, Drolet BA, et al. Tuberous Sclerosis Complex Associated with Vascular Anomalies or Overgrowth. Pediatr Dermatol 2016; 33:536.</a></li><li><a class="nounderline abstract_t">Geffrey AL, Shinnick JE, Staley BA, et al. Lymphedema in tuberous sclerosis complex. Am J Med Genet A 2014; 164A:1438.</a></li><li><a class="nounderline abstract_t">Navarre P, Poitras B. Lymphoedema in tuberous sclerosis: case report and review of the literature. J Pediatr Orthop 2014; 34:e27.</a></li><li><a class="nounderline abstract_t">Yates JR, Maclean C, Higgins JN, et al. The Tuberous Sclerosis 2000 Study: presentation, initial assessments and implications for diagnosis and management. Arch Dis Child 2011; 96:1020.</a></li><li><a class="nounderline abstract_t">Staley BA, Vail EA, Thiele EA. Tuberous sclerosis complex: diagnostic challenges, presenting symptoms, and commonly missed signs. Pediatrics 2011; 127:e117.</a></li><li><a class="nounderline abstract_t">Datta AN, Hahn CD, Sahin M. Clinical presentation and diagnosis of tuberous sclerosis complex in infancy. J Child Neurol 2008; 23:268.</a></li><li><a class="nounderline abstract_t">Inoue Y, Nemoto Y, Murata R, et al. CT and MR imaging of cerebral tuberous sclerosis. Brain Dev 1998; 20:209.</a></li><li><a class="nounderline abstract_t">Józwiak S, Schwartz RA, Janniger CK, Bielicka-Cymerman J. Usefulness of diagnostic criteria of tuberous sclerosis complex in pediatric patients. J Child Neurol 2000; 15:652.</a></li><li><a class="nounderline abstract_t">Altman NR, Purser RK, Post MJ. Tuberous sclerosis: characteristics at CT and MR imaging. Radiology 1988; 167:527.</a></li><li><a class="nounderline abstract_t">Kingsley DP, Kendall BE, Fitz CR. Tuberous sclerosis: a clinicoradiological evaluation of 110 cases with particular reference to atypical presentation. Neuroradiology 1986; 28:38.</a></li><li><a class="nounderline abstract_t">Goodman M, Lamm SH, Engel A, et al. Cortical tuber count: a biomarker indicating neurologic severity of tuberous sclerosis complex. J Child Neurol 1997; 12:85.</a></li><li><a class="nounderline abstract_t">Jansen FE, Vincken KL, Algra A, et al. Cognitive impairment in tuberous sclerosis complex is a multifactorial condition. Neurology 2008; 70:916.</a></li><li><a class="nounderline abstract_t">Chu-Shore CJ, Major P, Montenegro M, Thiele E. Cyst-like tubers are associated with TSC2 and epilepsy in tuberous sclerosis complex. Neurology 2009; 72:1165.</a></li><li><a class="nounderline abstract_t">Goh S, Butler W, Thiele EA. Subependymal giant cell tumors in tuberous sclerosis complex. Neurology 2004; 63:1457.</a></li><li><a class="nounderline abstract_t">Nishio S, Morioka T, Suzuki S, et al. Subependymal giant cell astrocytoma: clinical and neuroimaging features of four cases. J Clin Neurosci 2001; 8:31.</a></li><li><a class="nounderline abstract_t">Torres OA, Roach ES, Delgado MR, et al. Early diagnosis of subependymal giant cell astrocytoma in patients with tuberous sclerosis. J Child Neurol 1998; 13:173.</a></li><li><a class="nounderline abstract_t">Crino PB, Henske EP. New developments in the neurobiology of the tuberous sclerosis complex. Neurology 1999; 53:1384.</a></li><li><a class="nounderline abstract_t">Shepherd CW, Gomez MR, Lie JT, Crowson CS. Causes of death in patients with tuberous sclerosis. Mayo Clin Proc 1991; 66:792.</a></li><li><a class="nounderline abstract_t">Braffman BH, Bilaniuk LT, Naidich TP, et al. MR imaging of tuberous sclerosis: pathogenesis of this phakomatosis, use of gadopentetate dimeglumine, and literature review. Radiology 1992; 183:227.</a></li><li><a class="nounderline abstract_t">Nabbout R, Santos M, Rolland Y, et al. Early diagnosis of subependymal giant cell astrocytoma in children with tuberous sclerosis. J Neurol Neurosurg Psychiatry 1999; 66:370.</a></li><li><a class="nounderline abstract_t">Webb DW, Fryer AE, Osborne JP. Morbidity associated with tuberous sclerosis: a population study. Dev Med Child Neurol 1996; 38:146.</a></li><li><a class="nounderline abstract_t">O'Callaghan FJ, Martyn CN, Renowden S, et al. Subependymal nodules, giant cell astrocytomas and the tuberous sclerosis complex: a population-based study. Arch Dis Child 2008; 93:751.</a></li><li><a class="nounderline abstract_t">Houser OW, Gomez MR. CT and MR imaging of intracranial tuberous sclerosis. J Dermatol 1992; 19:904.</a></li><li><a class="nounderline abstract_t">Shepherd CW, Scheithauer BW, Gomez MR, et al. Subependymal giant cell astrocytoma: a clinical, pathological, and flow cytometric study. Neurosurgery 1991; 28:864.</a></li><li><a class="nounderline abstract_t">Griffiths PD, Bolton P, Verity C. White matter abnormalities in tuberous sclerosis complex. Acta Radiol 1998; 39:482.</a></li><li><a class="nounderline abstract_t">Iwasaki S, Nakagawa H, Kichikawa K, et al. MR and CT of tuberous sclerosis: linear abnormalities in the cerebral white matter. AJNR Am J Neuroradiol 1990; 11:1029.</a></li><li><a class="nounderline abstract_t">Mizuguchi M, Takashima S. Neuropathology of tuberous sclerosis. Brain Dev 2001; 23:508.</a></li><li><a class="nounderline abstract_t">Garaci FG, Floris R, Bozzao A, et al. Increased brain apparent diffusion coefficient in tuberous sclerosis. Radiology 2004; 232:461.</a></li><li><a class="nounderline abstract_t">Boronat S, Caruso P, Auladell M, et al. Arachnoid cysts in tuberous sclerosis complex. Brain Dev 2014; 36:801.</a></li><li><a class="nounderline abstract_t">Joinson C, O'Callaghan FJ, Osborne JP, et al. Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex. Psychol Med 2003; 33:335.</a></li><li><a class="nounderline abstract_t">Webb DW, Fryer AE, Osborne JP. On the incidence of fits and mental retardation in tuberous sclerosis. J Med Genet 1991; 28:395.</a></li><li><a class="nounderline abstract_t">Chu-Shore CJ, Major P, Camposano S, et al. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia 2010; 51:1236.</a></li><li><a class="nounderline abstract_t">Riikonen R, Simell O. Tuberous sclerosis and infantile spasms. Dev Med Child Neurol 1990; 32:203.</a></li><li class="breakAll">Westmoreland BF. The electroencephalogram in tuberous sclerosis. In: Tuberous Sclerosis Complex: Developmental Perspectives in Psychiatry, 3rd edition, Gomez MR, Sampson JR, Whittemore VH (Eds), Oxford University Press, New York 1999. p.63.</li><li><a class="nounderline abstract_t">de Groen AC, Bolton J, Bergin AM, et al. The Evolution of Subclinical Seizures in Children With Tuberous Sclerosis Complex. J Child Neurol 2019; 34:770.</a></li><li><a class="nounderline abstract_t">Farach LS, Richard MA, Lupo PJ, et al. Epilepsy Risk Prediction Model for Patients With Tuberous Sclerosis Complex. Pediatr Neurol 2020; 113:46.</a></li><li><a class="nounderline abstract_t">Thiele EA. Managing and understanding epilepsy in tuberous sclerosis complex. Epilepsia 2010; 51 Suppl 1:90.</a></li><li><a class="nounderline abstract_t">Curatolo P, Moavero R, de Vries PJ. Neurological and neuropsychiatric aspects of tuberous sclerosis complex. Lancet Neurol 2015; 14:733.</a></li><li><a class="nounderline abstract_t">Krueger DA, Northrup H, International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 2013; 49:255.</a></li><li><a class="nounderline abstract_t">McClintock WM. Neurologic manifestations of tuberous sclerosis complex. Curr Neurol Neurosci Rep 2002; 2:158.</a></li><li><a class="nounderline abstract_t">Jozwiak S, Goodman M, Lamm SH. Poor mental development in patients with tuberous sclerosis complex: clinical risk factors. Arch Neurol 1998; 55:379.</a></li><li><a class="nounderline abstract_t">Humphrey A, MacLean C, Ploubidis GB, et al. Intellectual development before and after the onset of infantile spasms: a controlled prospective longitudinal study in tuberous sclerosis. Epilepsia 2014; 55:108.</a></li><li><a class="nounderline abstract_t">Muzykewicz DA, Costello DJ, Halpern EF, Thiele EA. Infantile spasms in tuberous sclerosis complex: prognostic utility of EEG. Epilepsia 2009; 50:290.</a></li><li><a class="nounderline abstract_t">Winterkorn EB, Pulsifer MB, Thiele EA. Cognitive prognosis of patients with tuberous sclerosis complex. Neurology 2007; 68:62.</a></li><li><a class="nounderline abstract_t">O'Callaghan FJ, Harris T, Joinson C, et al. The relation of infantile spasms, tubers, and intelligence in tuberous sclerosis complex. Arch Dis Child 2004; 89:530.</a></li><li><a class="nounderline abstract_t">Kassiri J, Snyder TJ, Bhargava R, et al. Cortical tubers, cognition, and epilepsy in tuberous sclerosis. Pediatr Neurol 2011; 44:328.</a></li><li><a class="nounderline abstract_t">Gupta A, de Bruyn G, Tousseyn S, et al. Epilepsy and Neurodevelopmental Comorbidities in Tuberous Sclerosis Complex: A Natural History Study. Pediatr Neurol 2020; 106:10.</a></li><li><a class="nounderline abstract_t">Gillberg IC, Gillberg C, Ahlsén G. Autistic behaviour and attention deficits in tuberous sclerosis: a population-based study. Dev Med Child Neurol 1994; 36:50.</a></li><li><a class="nounderline abstract_t">Hunt A, Shepherd C. A prevalence study of autism in tuberous sclerosis. J Autism Dev Disord 1993; 23:323.</a></li><li><a class="nounderline abstract_t">Staley BA, Montenegro MA, Major P, et al. Self-injurious behavior and tuberous sclerosis complex: frequency and possible associations in a population of 257 patients. Epilepsy Behav 2008; 13:650.</a></li><li><a class="nounderline abstract_t">Kopp CM, Muzykewicz DA, Staley BA, et al. Behavior problems in children with tuberous sclerosis complex and parental stress. Epilepsy Behav 2008; 13:505.</a></li><li><a class="nounderline abstract_t">Jeste SS, Varcin KJ, Hellemann GS, et al. Symptom profiles of autism spectrum disorder in tuberous sclerosis complex. Neurology 2016; 87:766.</a></li><li><a class="nounderline abstract_t">Capal JK, Williams ME, Pearson DA, et al. Profile of Autism Spectrum Disorder in Tuberous Sclerosis Complex: Results from a Longitudinal, Prospective, Multisite Study. Ann Neurol 2021; 90:874.</a></li><li><a class="nounderline abstract_t">Bolton PF, Park RJ, Higgins JN, et al. Neuro-epileptic determinants of autism spectrum disorders in tuberous sclerosis complex. Brain 2002; 125:1247.</a></li><li><a class="nounderline abstract_t">Cohen AL, Kroeck MR, Wall J, et al. Tubers Affecting the Fusiform Face Area Are Associated with Autism Diagnosis. Ann Neurol 2023; 93:577.</a></li><li><a class="nounderline abstract_t">Walz NC, Byars AW, Egelhoff JC, Franz DN. Supratentorial tuber location and autism in tuberous sclerosis complex. J Child Neurol 2002; 17:830.</a></li><li><a class="nounderline abstract_t">de Vries PJ, Wilde L, de Vries MC, et al. A clinical update on tuberous sclerosis complex-associated neuropsychiatric disorders (TAND). Am J Med Genet C Semin Med Genet 2018; 178:309.</a></li><li><a class="nounderline abstract_t">Muzykewicz DA, Newberry P, Danforth N, et al. Psychiatric comorbid conditions in a clinic population of 241 patients with tuberous sclerosis complex. Epilepsy Behav 2007; 11:506.</a></li><li><a class="nounderline abstract_t">de Vries PJ, Hunt A, Bolton PF. The psychopathologies of children and adolescents with tuberous sclerosis complex (TSC): a postal survey of UK families. Eur Child Adolesc Psychiatry 2007; 16:16.</a></li><li><a class="nounderline abstract_t">D'Agati E, Moavero R, Cerminara C, Curatolo P. Attention-deficit hyperactivity disorder (ADHD) and tuberous sclerosis complex. J Child Neurol 2009; 24:1282.</a></li><li><a class="nounderline abstract_t">Kingswood JC, d'Augères GB, Belousova E, et al. TuberOus SClerosis registry to increase disease Awareness (TOSCA) - baseline data on 2093 patients. Orphanet J Rare Dis 2017; 12:2.</a></li><li><a class="nounderline abstract_t">Webb DW, Clarke A, Fryer A, Osborne JP. The cutaneous features of tuberous sclerosis: a population study. Br J Dermatol 1996; 135:1.</a></li><li><a class="nounderline abstract_t">Aldrich CS, Hong CH, Groves L, et al. Acral lesions in tuberous sclerosis complex: insights into pathogenesis. J Am Acad Dermatol 2010; 63:244.</a></li><li><a class="nounderline abstract_t">Jóźwiak S, Schwartz RA, Janniger CK, et al. Skin lesions in children with tuberous sclerosis complex: their prevalence, natural course, and diagnostic significance. Int J Dermatol 1998; 37:911.</a></li><li><a class="nounderline abstract_t">Zeller J, Friedmann D, Clerici T, Revuz J. The significance of a single periungual fibroma: report of seven cases. Arch Dermatol 1995; 131:1465.</a></li><li><a class="nounderline abstract_t">Bongiorno MA, Nathan N, Oyerinde O, et al. Clinical Characteristics of Connective Tissue Nevi in Tuberous Sclerosis Complex With Special Emphasis on Shagreen Patches. JAMA Dermatol 2017; 153:660.</a></li><li><a class="nounderline abstract_t">Roach ES, DiMario FJ, Kandt RS, Northrup H. Tuberous Sclerosis Consensus Conference: recommendations for diagnostic evaluation. National Tuberous Sclerosis Association. J Child Neurol 1999; 14:401.</a></li><li><a class="nounderline abstract_t">Rowley SA, O'Callaghan FJ, Osborne JP. Ophthalmic manifestations of tuberous sclerosis: a population based study. Br J Ophthalmol 2001; 85:420.</a></li><li><a class="nounderline abstract_t">Korol UB, Schoor R, Nanda V, et al. Gingival enlargement as a manifestation of tuberous sclerosis: case report and periodontal management. J Periodontol 2008; 79:759.</a></li><li><a class="nounderline abstract_t">Ammari MM, Ribeiro de Souza IP, Maia LC, Primo LG. Oral findings in a family with Tuberous sclerosis complex. Spec Care Dentist 2015; 35:261.</a></li><li><a class="nounderline abstract_t">Scully C. Orofacial manifestations in tuberous sclerosis. Oral Surg Oral Med Oral Pathol 1977; 44:706.</a></li><li><a class="nounderline abstract_t">Sparling JD, Hong CH, Brahim JS, et al. Oral findings in 58 adults with tuberous sclerosis complex. J Am Acad Dermatol 2007; 56:786.</a></li><li><a class="nounderline abstract_t">Hinton RB, Prakash A, Romp RL, et al. Cardiovascular manifestations of tuberous sclerosis complex and summary of the revised diagnostic criteria and surveillance and management recommendations from the International Tuberous Sclerosis Consensus Group. J Am Heart Assoc 2014; 3:e001493.</a></li><li><a class="nounderline abstract_t">Jóźwiak S, Domańska-Pakieła D, Kwiatkowski DJ, Kotulska K. Multiple cardiac rhabdomyomas as a sole symptom of tuberous sclerosis complex: case report with molecular confirmation. J Child Neurol 2005; 20:988.</a></li><li><a class="nounderline abstract_t">Webb DW, Thomas RD, Osborne JP. Cardiac rhabdomyomas and their association with tuberous sclerosis. Arch Dis Child 1993; 68:367.</a></li></ol></div><div id="topicVersionRevision">Topic 6175 Version 47.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17005952" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The tuberous sclerosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17637444" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Tuberous sclerosis complex: advances in diagnosis, genetics, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18722871" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Tuberous sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2039137" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Epidemiology of tuberous sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21692602" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Burden of disease and unmet needs in tuberous sclerosis complex with neurological manifestations: systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26800857" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : An estimation of the incidence of tuberous sclerosis complex in a nationwide retrospective cohort study (1997-2010).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34399110" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31084624" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Correction to: Incidence of tuberous sclerosis and age at first diagnosis: new data and emerging trends from a national, prospective surveillance study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30016967" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Incidence of tuberous sclerosis and age at first diagnosis: new data and emerging trends from a national, prospective surveillance study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30255984" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Genetics, genomics, and genotype-phenotype correlations of TSC: Insights for clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26022167" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Tuberous sclerosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8423606" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Variability of expression in tuberous sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18174550" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Intrafamilial phenotypic variability in tuberous sclerosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26067122" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The road to Vogt's triad.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11241138" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Aortic aneurysms in children and young adults with tuberous sclerosis: report of two cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27470532" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Tuberous Sclerosis Complex Associated with Vascular Anomalies or Overgrowth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24668795" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Lymphedema in tuberous sclerosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24992349" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Lymphoedema in tuberous sclerosis: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21813552" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The Tuberous Sclerosis 2000 Study: presentation, initial assessments and implications for diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21173003" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Tuberous sclerosis complex: diagnostic challenges, presenting symptoms, and commonly missed signs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18230839" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Clinical presentation and diagnosis of tuberous sclerosis complex in infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9661965" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : CT and MR imaging of cerebral tuberous sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11063078" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Usefulness of diagnostic criteria of tuberous sclerosis complex in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3357966" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Tuberous sclerosis: characteristics at CT and MR imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3951687" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Tuberous sclerosis: a clinicoradiological evaluation of 110 cases with particular reference to atypical presentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9075016" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Cortical tuber count: a biomarker indicating neurologic severity of tuberous sclerosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18032744" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Cognitive impairment in tuberous sclerosis complex is a multifactorial condition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19332694" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Cyst-like tubers are associated with TSC2 and epilepsy in tuberous sclerosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15505165" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Subependymal giant cell tumors in tuberous sclerosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11322123" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Subependymal giant cell astrocytoma: clinical and neuroimaging features of four cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9568761" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Early diagnosis of subependymal giant cell astrocytoma in patients with tuberous sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10534239" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : New developments in the neurobiology of the tuberous sclerosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1861550" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Causes of death in patients with tuberous sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1549677" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : MR imaging of tuberous sclerosis: pathogenesis of this phakomatosis, use of gadopentetate dimeglumine, and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10084537" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Early diagnosis of subependymal giant cell astrocytoma in children with tuberous sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8603782" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Morbidity associated with tuberous sclerosis: a population study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18456692" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Subependymal nodules, giant cell astrocytomas and the tuberous sclerosis complex: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1293181" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : CT and MR imaging of intracranial tuberous sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2067610" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Subependymal giant cell astrocytoma: a clinical, pathological, and flow cytometric study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9755694" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : White matter abnormalities in tuberous sclerosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2120978" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : MR and CT of tuberous sclerosis: linear abnormalities in the cerebral white matter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11701246" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Neuropathology of tuberous sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15215545" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Increased brain apparent diffusion coefficient in tuberous sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24325802" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Arachnoid cysts in tuberous sclerosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12622312" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1870096" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : On the incidence of fits and mental retardation in tuberous sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20041940" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The natural history of epilepsy in tuberous sclerosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2155840" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Tuberous sclerosis and infantile spasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2155840" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Tuberous sclerosis and infantile spasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31290714" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The Evolution of Subclinical Seizures in Children With Tuberous Sclerosis Complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33011641" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Epilepsy Risk Prediction Model for Patients With Tuberous Sclerosis Complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20331728" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Managing and understanding epilepsy in tuberous sclerosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26067126" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Neurological and neuropsychiatric aspects of tuberous sclerosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24053983" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11898483" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Neurologic manifestations of tuberous sclerosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9520012" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Poor mental development in patients with tuberous sclerosis complex: clinical risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24417555" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Intellectual development before and after the onset of infantile spasms: a controlled prospective longitudinal study in tuberous sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18801034" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Infantile spasms in tuberous sclerosis complex: prognostic utility of EEG.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17200495" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Cognitive prognosis of patients with tuberous sclerosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15155396" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The relation of infantile spasms, tubers, and intelligence in tuberous sclerosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21481739" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Cortical tubers, cognition, and epilepsy in tuberous sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32139167" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Epilepsy and Neurodevelopmental Comorbidities in Tuberous Sclerosis Complex: A Natural History Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8132114" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Autistic behaviour and attention deficits in tuberous sclerosis: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8331050" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A prevalence study of autism in tuberous sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18703161" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Self-injurious behavior and tuberous sclerosis complex: frequency and possible associations in a population of 257 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18602868" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Behavior problems in children with tuberous sclerosis complex and parental stress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27440144" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Symptom profiles of autism spectrum disorder in tuberous sclerosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34668231" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Profile of Autism Spectrum Disorder in Tuberous Sclerosis Complex: Results from a Longitudinal, Prospective, Multisite Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12023313" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Neuro-epileptic determinants of autism spectrum disorders in tuberous sclerosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36394118" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Tubers Affecting the Fusiform Face Area Are Associated with Autism Diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12585723" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Supratentorial tuber location and autism in tuberous sclerosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30117265" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : A clinical update on tuberous sclerosis complex-associated neuropsychiatric disorders (TAND).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17936687" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Psychiatric comorbid conditions in a clinic population of 241 patients with tuberous sclerosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17268883" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : The psychopathologies of children and adolescents with tuberous sclerosis complex (TSC): a postal survey of UK families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19805824" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Attention-deficit hyperactivity disorder (ADHD) and tuberous sclerosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28057044" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : TuberOus SClerosis registry to increase disease Awareness (TOSCA) - baseline data on 2093 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8776349" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : The cutaneous features of tuberous sclerosis: a population study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20462663" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Acral lesions in tuberous sclerosis complex: insights into pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9888331" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Skin lesions in children with tuberous sclerosis complex: their prevalence, natural course, and diagnostic significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7492148" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : The significance of a single periungual fibroma: report of seven cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28445558" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Clinical Characteristics of Connective Tissue Nevi in Tuberous Sclerosis Complex With Special Emphasis on Shagreen Patches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10385849" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Tuberous Sclerosis Consensus Conference: recommendations for diagnostic evaluation. National Tuberous Sclerosis Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11264130" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Ophthalmic manifestations of tuberous sclerosis: a population based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18380572" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Gingival enlargement as a manifestation of tuberous sclerosis: case report and periodontal management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25472033" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Oral findings in a family with Tuberous sclerosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/270067" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Orofacial manifestations in tuberous sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17239986" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Oral findings in 58 adults with tuberous sclerosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25424575" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Cardiovascular manifestations of tuberous sclerosis complex and summary of the revised diagnostic criteria and surveillance and management recommendations from the International Tuberous Sclerosis Consensus Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16417848" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Multiple cardiac rhabdomyomas as a sole symptom of tuberous sclerosis complex: case report with molecular confirmation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8466239" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Cardiac rhabdomyomas and their association with tuberous sclerosis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
